Tumor-associated calcium signal transducer 2 (TACSTD2)
tumor-associated calcium signal transducer 2 (TROP2), encoded by the TACSTD2 gene and also known as trophoblast cell-surface antigen 2 (Trop-2), is a type I transmembrane glycoprotein that was originally identified on trophoblast cells of the placenta.
tumor-associated calcium signal transducer 2 (TROP2), encoded by the TACSTD2 gene and also known as trophoblast cell-surface antigen 2 (Trop-2), is a type I transmembrane glycoprotein that was originally identified on trophoblast cells of the placenta. It functions as a calcium signal transducer and is implicated in the regulation of cell proliferation, survival, and adhesion. Under normal physiological conditions, TROP2 expression is restricted to a limited set of epithelial tissues; however, it is broadly and frequently overexpressed across a wide range of solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic cancer, and breast, gastric, and urothelial carcinomas. This tumor-enriched expression pattern, combined with its extracellular accessibility as a membrane-bound antigen, makes TROP2 a highly attractive therapeutic target.
The protein's association with cancer invasiveness and poorer patient outcomes has driven extensive efforts to exploit it as an antibody-drug conjugate (ADC) target. Several TROP2-directed ADCs have advanced through clinical development, with at least one receiving regulatory approval from both the Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) for use in patients with EGFR-mutated locally advanced or metastatic NSCLC whose disease has progressed after EGFR-directed therapy and platinum-based chemotherapy. Beyond ADCs, TROP2 is now being explored in radioimmunotherapy, bispecific antibody formats, and proteolysis-targeting chimera (PROTAC)-based platforms, reflecting its versatility as an oncological target.
Where the papers sit
16 papers from the last 6 months study Tumor-associated calcium signal transducer 2 (TACSTD2) directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 2 observational · 3 human data · 7 preclinical · 2 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
TROP2-Directed ADCs in Cancer
TROP2 expression is being used to select and monitor antibody-drug conjugate treatment across breast, bladder, and EBV-positive gastric cancers. Sacituzumab govitecan and related TROP2-directed ADCs recur alongside immunohistochemistry, H-scores, circulating tumor cells, survival, and safety management. Studies also extend the platform toward Nectin-4/TROP2 theranostics and drug-tolerant persister cells. Expression is promising as a biomarker, but its predictive value and optimal toxicity management remain unresolved.
9 papers · 56.2%
-
TROP2 ADCs and Immunotherapy
TROP2 ADC therapy is moving toward immunotherapy combinations and earlier interception of acquired resistance. Sacituzumab tirumotecan with pembrolizumab is being tested in PD-L1-positive NSCLC and advanced TNBC, with progression-free survival as a key endpoint. Real-world studies assess monotherapy and combinations in pretreated metastatic TNBC, while TROP2 targeting is used to delay EGFR-TKI resistance in drug-tolerant persister cells. Whether benefit depends on PD-L1 status or disease context remains open.
4 papers · 25%
-
Targeted Delivery in Pancreatic Cancer
Pancreatic cancer work is shifting toward selective payload delivery and multi-target immune engagement. TROP2 aptamers aim to internalize drugs into pancreatic tumors, while bispecific antibodies and TCR-JANUS engagers address oncogenic signaling and tumor heterogeneity. Immunogenic cell death and Calreticulin (CALR) recur as indicators of immune activation, alongside efforts to reduce toxicity. The shared goal is stronger, more selective antitumor activity, but comparative clinical evidence is not yet established.
3 papers · 18.8%
TROP2 is a tumor-addressing module for therapies beyond antibody-drug conjugates
In TCR-JANUS engager studies using a humanized KRAS-G12V-specific TCR-T model, and in preclinical colorectal and pancreatic cancer models using a TROP2-targeted anti-Frizzled bispecific antibody, TROP2 was used not simply to deliver an ADC payload but to redirect T cells or selectively inhibit an oncogenic pathway (PMIDs 42715334, 42172336). Together, these studies replace the set’s prevailing ADC-centered view with a broader one: TROP2 can function as a tumor-selective address for distinct therapeutic effectors, enabling dual-antigen immune recognition or tumor-restricted Wnt inhibition while limiting damage to normal tissue.
TROP2 is an inducible maintenance dependency of EGFR-inhibitor-tolerant lung cancer cells
In EGFR-mutant non-small-cell lung cancer models treated with osimertinib and sacituzumab tirumotecan, TROP2 was found to be dynamically upregulated during formation of drug-tolerant persister cells and to contribute functionally to their maintenance 42314664Jun. This assigns TROP2 a role outside the usual constitutive tumor-surface target or biomarker framework: EGFR inhibition itself creates a TROP2-dependent residual population, supporting an “induce-target-kill” strategy in which TROP2-directed treatment is used to prevent or delay acquired resistance.
Papers
The 16 papers from the last 6 months that study Tumor-associated calcium signal transducer 2 (TACSTD2) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
TROP2-Directed ADCs in Cancer (9)
- Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer. Molecular pharmaceutics · 2 Nov 2026 PMID 42969724
- High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates. Langenbeck's archives of surgery · 24 Oct 2026 PMID 42925415
- Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
- TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665429
- The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer. Journal of cancer research and clinical oncology · 17 Jul 2026 PMID 42467304
- Bimodality in pan-cancer proteomics reveals new opportunities for biomarker discovery. Genome biology · 10 Jul 2026 PMID 42426806
- Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. Journal of medicinal chemistry · 1 Jul 2026 PMID 42381118
- Targeting drug-tolerant persister cells: Let's bring on the TROPs! Cancer cell · 18 Jun 2026 PMID 42314666
- Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells. Proceedings of the National Academy of Sciences of the United States of America · 17 Jun 2026 PMID 42308036
TROP2 ADCs and Immunotherapy (4)
- Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
- TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England) · 31 Jul 2026 PMID 42535874
- Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer cell · 18 Jun 2026 PMID 42314664
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
Targeted Delivery in Pancreatic Cancer (3)
- A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer. Science advances · 11 Nov 2026 PMID 43013672
- TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
- Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity. Science advances · 22 May 2026 PMID 42172336
By study type
Clinical trials (2)
- TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England) · 31 Jul 2026 PMID 42535874
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
Observational studies and case reports (2)
- Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
- Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells. Proceedings of the National Academy of Sciences of the United States of America · 17 Jun 2026 PMID 42308036
Human data, design not indexed (3)
- High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates. Langenbeck's archives of surgery · 24 Oct 2026 PMID 42925415
- TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665429
- The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer. Journal of cancer research and clinical oncology · 17 Jul 2026 PMID 42467304
Preclinical: animal, cell and lab studies (7)
- A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer. Science advances · 11 Nov 2026 PMID 43013672
- Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer. Molecular pharmaceutics · 2 Nov 2026 PMID 42969724
- TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
- Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. Journal of medicinal chemistry · 1 Jul 2026 PMID 42381118
- Targeting drug-tolerant persister cells: Let's bring on the TROPs! Cancer cell · 18 Jun 2026 PMID 42314666
- Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer cell · 18 Jun 2026 PMID 42314664
- Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity. Science advances · 22 May 2026 PMID 42172336
Unclassified: not yet indexed with MeSH (2)
- Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
- Bimodality in pan-cancer proteomics reveals new opportunities for biomarker discovery. Genome biology · 10 Jul 2026 PMID 42426806
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-20 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.